United States - English - NLM (National Library of Medicine)

physicians total care, inc. - dihydrocodeine bitartrate (unii: 8lxs95bsa9) (dihydrocodeine - unii:n9i9hdb855), acetaminophen (unii: 362o9itl9d) (acetaminophen - unii:362o9itl9d), caffeine (unii: 3g6a5w338e) (caffeine - unii:3g6a5w338e) - dihydrocodeine bitartrate 32 mg - acetaminophen, caffeine, and dihydrocodeine bitartrate tablets are indicated for the relief of moderate to moderately severe pain. this combination product is contraindicated in persons with hypersensitivity to dihydrocodeine, codeine, acetaminophen, caffeine, or any of the inactive components listed above, or any situation where opioids are contraindicated including significant respiratory depression (in unmonitored settings or in the absence of resuscitative equipment), acute or severe bronchial asthma or hypercapnia, and paralytic ileus. this combination product is subject to the provisions of the controlled substance act, and has been placed in schedule iii. dihydrocodeine can produce drug dependence of the codeine type and therefore has the potential of being abused. like other opioid analgesics, dihydrocodeine may produce subjective effects other than analgesia (e.g., euphoria, relaxation), which may contribute to abuse by some patients. psychological dependence, physical dependence, and tolerance may d

New Zealand - English - Medsafe (Medicines Safety Authority)

noumed pharmaceuticals limited - codeine phosphate hemihydrate 15mg;  ;  ;  ;   - tablet - 15 mg - active: codeine phosphate hemihydrate 15mg         excipient: lactose monohydrate magnesium stearate maize starch - codeine phosphate is indicated for: the relief of mild to moderate pain (including pain associated with terminal illness, post-operative pain and headache), the relief of symptoms of diarrhoea (except diarrhoea caused by poisoning),

New Zealand - English - Medsafe (Medicines Safety Authority)

noumed pharmaceuticals limited - codeine phosphate hemihydrate 30mg;  ;  ;  ;   - tablet - 30 mg - active: codeine phosphate hemihydrate 30mg         excipient: acacia lactose monohydrate magnesium stearate maize starch purified talc - codeine phosphate is indicated for: the relief of mild to moderate pain (including pain associated with terminal illness, post-operative pain and headache), the relief of symptoms of diarrhoea (except diarrhoea caused by poisoning),

New Zealand - English - Medsafe (Medicines Safety Authority)

noumed pharmaceuticals limited - codeine phosphate hemihydrate 60mg;  ;  ;  ;   - tablet - 60 mg - active: codeine phosphate hemihydrate 60mg         excipient: lactose monohydrate magnesium stearate maize starch - codeine phosphate is indicated for: the relief of mild to moderate pain (including pain associated with terminal illness, post-operative pain and headache), the relief of symptoms of diarrhoea (except diarrhoea caused by poisoning),

United States - English - NLM (National Library of Medicine)

akorn - codeine phosphate (unii: gsl05y1mn6) (codeine anhydrous - unii:ux6owy2v7j), promethazine hydrochloride (unii: r61zeh7i1i) (promethazine - unii:ff28ejq494) - codeine phosphate 10 mg in 5 ml - promethazine hcl and codeine phosphate oral solution is indicated for the temporary relief of coughs and upper respiratory symptoms associated with allergy or the common cold in patients 18 years of age and older. important limitations of use: promethazine hcl and codeine phosphate oral solution is contraindicated for: promethazine hcl and codeine phosphate oral solution is also contraindicated in patients with: risk summary promethazine hcl and codeine phosphate oral solution is not recommended for use in pregnant women, including during or immediately prior to labor. prolonged use of opioids during pregnancy may cause neonatal opioid withdrawal syndrome [see warnings and precautions (5.19), clinical considerations ]. there are no available data with promethazine hcl and codeine phosphate oral solution use in pregnant women to inform a drug-associated risk for adverse developmental outcomes. published studies with codeine have reported inconsistent findings and have important methodological limitations (see

Canada - English - Health Canada

pendopharm division of pharmascience inc - acetylsalicylic acid; caffeine (caffeine citrate); codeine phosphate - tablet - 375mg; 30mg; 15mg - acetylsalicylic acid 375mg; caffeine (caffeine citrate) 30mg; codeine phosphate 15mg - salicylates

Canada - English - Health Canada

pendopharm division of pharmascience inc - acetylsalicylic acid; caffeine (caffeine citrate); codeine phosphate - tablet - 375mg; 15mg; 30mg - acetylsalicylic acid 375mg; caffeine (caffeine citrate) 15mg; codeine phosphate 30mg - opiate agonists

Malta - English - Medicines Authority

lcm limited linthwaite laboratories, huddersfield, hd7 5qh, united kingdom - codeine phosphate - oral solution - codeine phosphate 15 mg/5ml - cough and cold preparations

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - paracetamol, quantity: 500 mg; codeine phosphate hemihydrate, quantity: 30 mg - tablet, uncoated - excipient ingredients: potassium sorbate; maize starch; povidone; purified talc; stearic acid; magnesium stearate; microcrystalline cellulose; croscarmellose sodium; pregelatinised maize starch - paracetamol/codeine gh 500/30 is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

Canada - English - Health Canada

purdue pharma - codeine (codeine monohydrate, codeine sulfate trihydrate) - tablet (extended-release) - 200mg - codeine (codeine monohydrate, codeine sulfate trihydrate) 200mg - opiate agonists